This session at ACR Convergence will focus on early biomarkers for diagnostic and prognostic purposes, as well as the description of current treatment guidelines from multiple societies. The speakers will discuss the role of repeated biopsy to assess response and maintenance therapy, and describe some promising new therapies under development. Watch for it on Sunday,…
Pain in RA and OA: ACR Convergence 2020 Preview
Patients with RA and OA have joint pain, and pain is the primary reason patients seek care. The mechanisms responsible for the pain are now just beginning to be understood. This session, on Nov. 6, 4 p.m. EST, will cover the mechanisms responsible for the development of pain in both inflammatory and degenerative arthritis.
Racial Disparity in RA & OA: ACR Convergence 2020 Preview
Minority race/ethnicity are associated with more severe outcomes in OA and RA. Although African Americans have more symptomatic RA than whites, they are more likely to delay seeking care and initiating DMARDs and biologics. The session on Nov. 6, 3 p.m. EST, will review current outcomes data for RA and OA, including TKA, THA and…
Familial Patterns in Childhood- & Adult-Onset SLE
A study examining familial patterns of systemic lupus erythematosus (SLE) found a greater decline in SLE recurrence rate by generation in childhood- than in adult-onset SLE, suggesting adult-onset SLE may be characterized by environmental risk factors.
Ultrasound Provides Insights into Immune Checkpoint Inhibitor‐Induced Inflammatory Arthritis
Ultrasound may provide unique insights into the effects of immune checkpoint inhibitors on the human body beyond the immune system. Research suggests synovitis and inflammatory tendon involvement are commonly seen in patients with immune checkpoint inhibitor-induced inflammatory arthritis.
FDA Approves Tofacitinib for Young Patients with Active Polyarticular JIA
Tofacitinib is now FDA approved to treat patients 2 years and older with active, polyarticular juvenile idiopathic arthritis.
FDA Updates Boxed Warning of Benzodiazepines, Adding Risks for Abuse & Addiction
The FDA is requiring all benzodiazepines to carry an updated boxed warning that addresses the risks of misuse, abuse and addiction associated with their use.
Janus Kinase vs. TNF Inhibitors: The Context for Venous Thromboembolism Risk with RA Treatments
An observational study found treatment with tofacitinib resulted in only a slightly higher rate of venous thromboembolism than tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
Hardship Exception Applications Open for Clinicians Struggling with Quality Payment Program Reporting in 2020
The Centers for Medicare & Medicaid Services have provided the opportunity to apply for exceptions for the Performance Year (PY) 2020 Quality Payment Program Merit-Based Incentive Program (MIPS) program requirements. This will help clinicians finding PY2020 MIPS federal reporting difficult due to circumstances outside their control.
UHC Announces New Copay Accumulator Policy Affecting In-Office Treatments
Editor’s note Nov. 23, 2020: As of Nov. 12, 2020, UHC has delayed implementation of the policy discussed below. See “UnitedHealthcare Delays Copay Accumulator Policy.” UnitedHealthcare (UHC) announced that, as of Jan. 1, 2021, providers will be required to report the amount their patients receive in copay assistance for office-administered treatments. UHC will then use…
- « Previous Page
- 1
- …
- 179
- 180
- 181
- 182
- 183
- …
- 814
- Next Page »